Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17784698 | 0.84 | NSD2 (0.40) | PARGNSD2 | |
| SCHEMBL17784738 | 0.82 | CYP19A1 (0.38) | PARGCYP19A1CYP3A4SMN1; SMN2 | |
| SCHEMBL17784715 | 0.80 | CYP19A1 (0.40) | PARGCYP19A1CYP3A4 | |
| SCHEMBL17792629 | 0.78 | ALDH1A1 (0.31) | PARG | |
| Methane SCHEMBL17786217 | 0.78 | PARG (0.31) | PARG | |
| SCHEMBL17784726 | 0.69 | CYP24A1 (0.30) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL1314001 | 0.68 | AGXT (0.42) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL1179211 | 0.67 | CA2 (0.49) | SMN1; SMN2 | |
| SCHEMBL17784716 | 0.67 | ABL1 (0.36) | CYP19A1CYP3A4 | |
| SCHEMBL9347235 | 0.66 | ESR1 (0.43) | CYP19A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3224253-B1 | BIS (SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | GESYNTA PHARMA AB (SE) | 2019-10-30 | — | — | EP | disclosed |
| US-10081614-B2 | Bis(sulfonamide) derivatives and their use as mPGES inhibitors | ACTURUM REAL ESTATE AB (SE) | 2018-09-25 | — | — | US | disclosed |
| US-20180002278-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | ACTURUM REAL ESTATE AB (SE) | 2018-01-04 | — | — | US | disclosed |
| US-20170313672-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | GESYNTA PHARMA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313672-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | GESYNTA PHARMA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313672-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | GESYNTA PHARMA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| EP-3224253-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | Acturum Real Estate AB (SE) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016085392-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | Acturum Life Science AB (SE) | 2016-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10081614-B2 | Bis(sulfonamide) derivatives and their use as mPGES inhibitors | PTGES, PTGS1, PTGES2 | PARG 1284/4885CYP19A1 605/4885CYP3A4 268/4885 |
| US-20170313672-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | PTGES, PTGS1, PTGES2 | PARG 1284/4885CYP19A1 605/4885CYP3A4 268/4885 |
| US-20180002278-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | PTGES, PTGS1, PTGES2 | PARG 1284/4885CYP19A1 605/4885CYP3A4 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.